Elan Corporation

DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 3, 2004--Elan Corporation, plc today announced that Richard T. Collier would be joining the company as executive vice president and general counsel at the end of the month. Mr. Collier will have overall responsibility for Elan's legal organisation and become an integral part of the company's leadership team.

Mr. Collier is currently senior counsel, Life Sciences Interdisciplinary Group, at Morgan, Lewis & Bockius LLP, where he focuses on legal issues regarding pharmaceutical discovery, development, manufacture, marketing and sales. Prior to joining Morgan Lewis, he was senior vice president and general counsel at Pharmacia Corporation, after serving in that same position at Pharmacia & Upjohn. Prior to his experience at Pharmacia, Mr. Collier spent 11 years at Rhone-Poulenc Rorer, Inc. Previously, he was in private practice after having served with the U.S. Federal Trade Commission and U.S. Department of Justice.

Elan President and CEO Kelly Martin said, "This announcement exemplifies our commitment to adding significant talent and building a superior organisation. We look forward to Rick joining our team at this time, and we are confident that Elan will benefit from his experience and leadership."

About Elan

Elan is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing, selling and marketing advanced therapies in neurodegenerative diseases, autoimmune diseases and severe pain. Elan's (NYSE: ELN) shares trade on the New York, London and Dublin Stock Exchanges.

CONTACT: Elan Corporation
Investor Relations:
Emer Reynolds, 353-1-709-4000
800-252-3526
or
Media Relations:
Anita Kawatra, 212-407-5740
800-252-3526

SOURCE: Elan Corporation